- Home
- LITS vs ATRA Comparison
LITS vs ATRA Comparison
Compare LITS & ATRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LITS | ATRA |
|---|---|---|
| Founded | 2000 | 2012 |
| Country | United States | United States |
| Employees | 4 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 42.2M | 38.9M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | LITS | ATRA |
|---|---|---|
| Price | $1.15 | $5.18 |
| Analyst Decision | | Sell |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | ★ 287.2K | 244.1K |
| Earning Date | 05-12-2026 | 03-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 122.52 |
| EPS | N/A | ★ 2.57 |
| Revenue | N/A | ★ $120,772,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $1.84 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.95 | $3.92 |
| 52 Week High | $3.03 | $19.15 |
Technical Indicators
Market Signals| Indicator | LITS | ATRA |
|---|---|---|
| Relative Strength Index (RSI) | 47.11 | 48.73 |
| Support Level | $0.98 | $4.70 |
| Resistance Level | $1.16 | $5.65 |
| Average True Range (ATR) | 0.07 | 0.48 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 39.13 | 31.85 |
Price Performance
Historical ComparisonAbout LITS Lite Strategy Inc.
Lite Strategy Inc is focused on the clinical development of novel therapies for cancer. The company's portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor and zandelisib, an oral, once-daily, selective PI3K inhibitor. It is a clinical-stage pharmaceutical company committed to the development of novel and differentiated cancer therapies intended to improve outcomes for patients.
About ATRA Atara Biotherapeutics Inc.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).